glp 1 clinical studies The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award | Current Medicine GLP-1 Side Effects Statistics 2026

Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed even larger weight reductions in the SURMOUNT trialsup to 22% body weight loss at higher doses in non-diabetic obese individuals

[2] [3] Some GLP-1 medications are also specifically licensed for weight management in adults with obesity or overweight with comorbidities

Liraglutide, a once-daily subcutaneous injection, was assessed in a 48-week phase II trial involving patients with metabolic dysfunction-associated steatohepatitis (MASH)

If you already have diabetic retinopathy, diabetic macular edema, recent visual symptoms, or recent retinal treatment, ask for coordinated care between your diabetes doctor and your eye doctor before and during treatment

Slow, steady rotations